Omnicell (NASDAQ:OMCL) Stock Rating Lowered by Wall Street Zen

Omnicell (NASDAQ:OMCL) was downgraded by research analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a research note issued on Saturday.

OMCL has been the subject of several other reports. Piper Sandler reissued an “overweight” rating and set a $49.00 price objective (down from $63.00) on shares of Omnicell in a report on Friday. Weiss Ratings reissued a “sell (d+)” rating on shares of Omnicell in a research note on Thursday, January 22nd. Zacks Research lowered shares of Omnicell from a “strong-buy” rating to a “hold” rating in a report on Tuesday, December 9th. KeyCorp raised shares of Omnicell from a “sector weight” rating to an “overweight” rating and set a $60.00 target price for the company in a report on Wednesday, January 7th. Finally, Benchmark upped their target price on shares of Omnicell from $50.00 to $60.00 and gave the company a “buy” rating in a research report on Monday, February 2nd. Five analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $54.29.

Omnicell Trading Down 5.1%

Shares of OMCL stock opened at $37.07 on Friday. The firm has a fifty day moving average of $46.22 and a 200-day moving average of $37.11. The stock has a market cap of $1.66 billion, a price-to-earnings ratio of 926.98, a P/E/G ratio of 1.23 and a beta of 0.78. Omnicell has a 52-week low of $22.66 and a 52-week high of $55.00. The company has a debt-to-equity ratio of 0.14, a quick ratio of 1.22 and a current ratio of 1.43.

Omnicell (NASDAQ:OMCL) last issued its earnings results on Thursday, February 5th. The company reported $0.40 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.47 by ($0.07). Omnicell had a return on equity of 3.00% and a net margin of 0.17%.The company had revenue of $313.98 million during the quarter, compared to analyst estimates of $313.36 million. During the same period in the previous year, the company posted $0.60 earnings per share. The company’s quarterly revenue was up 2.3% on a year-over-year basis. Omnicell has set its Q1 2026 guidance at 0.260-0.360 EPS and its FY 2026 guidance at 1.650-1.850 EPS. On average, equities research analysts forecast that Omnicell will post 1.09 earnings per share for the current fiscal year.

Insider Buying and Selling at Omnicell

In other news, EVP Corey J. Manley sold 6,106 shares of the business’s stock in a transaction on Thursday, January 8th. The shares were sold at an average price of $49.90, for a total value of $304,689.40. Following the completion of the transaction, the executive vice president owned 91,674 shares of the company’s stock, valued at $4,574,532.60. The trade was a 6.24% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 2.52% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in OMCL. Raymond James Financial Inc. bought a new stake in shares of Omnicell in the second quarter worth about $26,000. First Horizon Corp acquired a new position in shares of Omnicell in the 3rd quarter valued at approximately $31,000. Farther Finance Advisors LLC increased its stake in Omnicell by 784.8% during the 3rd quarter. Farther Finance Advisors LLC now owns 1,168 shares of the company’s stock worth $36,000 after purchasing an additional 1,036 shares in the last quarter. LSV Asset Management acquired a new stake in Omnicell during the 3rd quarter worth approximately $97,000. Finally, Tower Research Capital LLC TRC lifted its stake in Omnicell by 385.5% in the second quarter. Tower Research Capital LLC TRC now owns 4,952 shares of the company’s stock valued at $146,000 after buying an additional 3,932 shares in the last quarter. 97.70% of the stock is currently owned by institutional investors.

Key Headlines Impacting Omnicell

Here are the key news stories impacting Omnicell this week:

• Positive Sentiment: Company raised FY‑2026 and Q1 guidance above Street estimates (FY EPS 1.65–1.85 vs. consensus ~1.53; Q1 EPS 0.26–0.36 vs. ~0.22) and set revenue target roughly $1.215B–$1.255B, signaling confidence in recovery and product-led growth. BusinessWire: FY & Q4 results
• Positive Sentiment: Analyst upgrade: Bank of America raised Omnicell to Buy, citing a new product cycle (Titan XT, OmniSphere) that could drive revenue revisions and multi‑year growth upside. Investing.com: BofA upgrade
• Neutral Sentiment: Management emphasized strong demand for new platforms (Titan XT, OmniSphere) on the earnings call and provided a slide deck; revenue was roughly in line with expectations (+2.3% YoY). Seeking Alpha: Earnings call transcript
• Negative Sentiment: Q4 EPS missed estimates ($0.40 vs. $0.47 consensus) and declined from $0.60 a year ago, highlighting near‑term margin pressures; investors punished the print despite revenue guidance upside. Zacks: EPS miss
• Negative Sentiment: Some sell‑side caution remains: BTIG reiterated a Hold, pointing to near‑term profitability headwinds and a premium valuation that could limit upside until margins improve. TipRanks: BTIG Hold
• Negative Sentiment: High intraday volume and headlines noting a share plunge reflect short‑term selling pressure as traders react to the EPS miss and margin commentary despite guidance. Yahoo Finance: Why shares plunging

About Omnicell

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.